Cullinan Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview

Cullinan Therapeutics

04/11/2024 15:47

* Cullinan Therapeutics Inc  CGEM.OQ   CGEM.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 6 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Cullinan Therapeutics
Inc is
for a loss of 81 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cullinan
Therapeutics Inc is $30.00​, above​ its last closing price
of $15.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.70       -0.73      -0.75     Missed  -3.4
 Mar. 31 2024  -0.99       -0.99      -0.86     Beat    13.1
 Jan. 1 0001   -0.95       -0.96      -0.54     Beat    43.8​
 Sep. 30 2023  -0.92       -0.92      -0.91     Beat    1.3
 ​​Jun.        -0.90       -0.97      -0.82     Beat    15.5
 30 2023                                                
 Mar. 31 2023  -1.00       -0.98      -1.42     Missed  -44.9​
 Dec. 31 2022  -0.63       -0.66      -0.59     Beat    11.3
 Sep. 30 2022  -0.95       -0.97      -0.54     Beat    44.1
 This summary was machine generated November 4 at 15:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)